Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Trogarzo

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Aug 13, 2021 1:09pm

77 Views

Post# 33701285

RE:RE:RE:Trogarzo

The report is the clinical trial protocol will be approved so the trial can start.

SPCEO1 wrote: We have found that you need to be careful with what Taimed says and/or how the taiwanese press reports what they said. Based on what THTX said, the IV Push formulation will not be approved by the FDA until the middle of 2022.

scarlet1967 wrote:
“The company expects to receive approval within the next few days, as the regulator had reviewed the protocol and approved it in principle, he said.”

https://www.taipeitimes.com/News/biz/archives/2021/08/14/2003762551